Q&A 26: Anti-CD20 therapy, hypogammaglobulinaemia and infection risk

Paid episode

The full episode is only available to paid subscribers of MS-Selfie

Q&A 26: Anti-CD20 therapy, hypogammaglobulinaemia and infection risk

I have hypogammaglobulinaemia; should I switch from ocrelizumab to teriflunomide? Does intermittent fasting increase your mortality? Will moving to a sunny country help my MS? ...


Q1: I am 36 years of age and have now been on ocrelizumab for over six years.  I am doing well on ocrelizumab with no relapses and a stable MRI. I also don’t think I have smouldering MS. However, my latest blood results show I have developed hypogammaglobulinaemia, and my neurologist now wants to switch me from ocrelizumab to teriflunomide. Do you agree with this? 

Q2: I have just read that intermittent fasting (IF) increases your mortality due to cardiovascular disease. Is this correct? Should I stop IF? 

Q3:  I am writing on behalf of my 16-year-old daughter, who was diagnosed with MS earlier this year. She has been put on ocrelizumab (Ocrevus). I want your opinion on whether moving to a sunny country further south of Europe, like Italy, would help with the disease's progression and severity.

NOTE: General substack newsletters and microsite are free; only Q&A sessions are restricted to paying subscribers. I can't run and maintain the MS-Selfie microsite, hence the need to pay people to help me do the work. If people want to ask medical questions unrelated to the Newsletters or Podcasts, they either need to become paying subscribers or email ( to request a complimentary subscription.


Listen to this episode with a 7-day free trial

Subscribe to MS-Selfie to listen to this post and get 7 days of free access to the full post archives.

MS-Selfie is a self-help resource for people with multiple sclerosis